The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RLAY | +17.26% | -83.32% | -30.1% | -80% |
| S&P | +18.54% | +92.9% | +14.04% | +111% |
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.68M | 0.0% |
| Gross Profit | -$0.33M | 76.2% |
| Gross Margin | -48.01% | 0.0% |
| Market Cap | $593.20M | -31.5% |
| Market Cap / Employee | $2.29M | 0.0% |
| Employees | 259 | 0.0% |
| Net Income | -$70.38M | 23.7% |
| EBITDA | -$75.85M | 31.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $113.94M | -15.0% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $30.66M | -33.0% |
| Short Term Debt | $3.53M | -33.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.50% | -4.3% |
| Return On Invested Capital | -31.82% | -4.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$55.29M | 16.0% |
| Operating Free Cash Flow | -$55.26M | 16.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.38 | 0.82 | 0.57 | 0.82 | -29.28% |
| Price to Sales | 99.21 | 68.89 | 57.74 | 70.92 | 188.32% |
| Price to Tangible Book Value | 1.39 | 0.82 | 0.57 | 0.82 | -29.26% |
| Enterprise Value to EBITDA | -2.14 | 0.52 | 2.63 | 0.40 | -119.17% |
| Return on Equity | -42.7% | -44.2% | -45.5% | -46.2% | 6.85% |
| Total Debt | $49.82M | $48.50M | $47.16M | $34.18M | -33.10% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
